Condition: Advanced Solid Tumor · High Grade Serous Adenocarcinoma of Ovary · Squamous Non-small-cell Lung Cancer · Sponsor: Volastra Therapeutics, Inc.
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
This description comes directly from the study's public registry record.
Volastra Therapeutics, Inc. · (646) 344-1248 · clinicaltrials@volastratx.com
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital | Newport Beach, California, United States | Recruiting |
| University of Colorado Cancer Center | Aurora, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Kellogg Cancer Center | Evanston, Illinois, United States | Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Recruiting |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Active Not Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| The Christ Hospital | Cincinnati, Ohio, United States | Recruiting |
| Women & Infants Hospital | Providence, Rhode Island, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05902988